Atopic Keratoconjunctivitis Market
Number of pages: 100 | Report Format: PDF | Published date: April 03, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market size value in 2022 |
US$ 587.2 million |
|
Revenue Forecast in 2031 |
US$ 1,098.9 million |
|
CAGR |
7.2% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Distribution Channel, and Region. |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global atopic keratoconjunctivitis market was valued at US$ 587.2 million in 2022 and is expected to register a revenue CAGR of 7.2% to reach US$ 1,098.9 million by 2031.
Atopic Keratoconjunctivitis Market Fundamentals
Atopic keratoconjunctivitis (AKC) is an extremely uncommon but potentially blinding eye disease. Atopic keratoconjunctivitis impacts 20% to 40% of individuals with atopic dermatitis. It is associated with an 87% prevalence of asthma and a 95% incidence of concurrent eczema. Adults with systemic atopic disease, especially atopic dermatitis, are affected, a lifelong condition. Contrary to vernal keratoconjunctivitis, the disease characteristically manifests in the late teens. However, it can rarely be obvious in childhood and is persistent and may advance relentlessly. Redness, itchiness, and eye secretion are signs of atopic keratoconjunctivitis. Topical corticosteroids, antihistamines, and recognizing and avoiding irritants may all be treatment choices for atopic keratoconjunctivitis. Additionally, systemic T cell and calcineurin inhibitor medications and novel drug delivery systems have been recently added to the arsenal of treatments for severe atopic keratoconjunctivitis, emphasizing steroid-sparing agents.
A novel medication named tacrolimus, a calcineurin inhibitor initially used to treat atopic dermatitis, has proven extremely effective in managing atopic keratoconjunctivitis. For patients with severe atopic keratoconjunctivitis, these novel therapies have shown promise in lowering the need for ongoing steroid use and enhancing the overall quality of life. Additional research is necessary to comprehend their effectiveness and potential side effects completely. Therefore, this treatment has produced excellent outcomes without any significant side effects. Due to its efficacy and safety record, it has gained popularity among physicians and patients. Research is still being done to investigate its possible applications in treating other medical conditions.
[90787]
Atopic Keratoconjunctivitis Market Dynamics
Globally expanding reactive conjunctivitis patient populations and rising demand for healthcare services is expected to significantly fuel market revenue growth. Additionally, as the patient population grows, atopic keratoconjunctivitis has a high occurrence rate globally. Many major market players are concentrating on R&D activities to create drugs for atopic keratoconjunctivitis. Additionally, the prevalence of seasonal allergies and allergies brought on by pollution is expected to spur market growth in the upcoming years. The increase in allergic conjunctivitis instances worldwide is also attributed to rising air pollution levels and shifting climatic patterns. These factors are expected to increase the demand for efficient treatment options, enriching the drug pipeline. During the forecast period, this tendency is expected to continue, presenting lucrative opportunities for market participants in the atopic keratoconjunctivitis market.
Additionally, a new treatment for allergic conjunctivitis is developing due to increased public knowledge of the importance of eye health and the accessibility of cutting-edge therapies. Due to various factors, including rapid urbanization, industrialization, and the rise in allergens, the prevalence of ocular allergies has grown significantly over the past few decades. To create effective therapeutics for atopic keratoconjunctivitis, many biopharmaceutical companies are involved in R&D efforts. Recent developments in the ocular allergy therapeutics market include developing novel drug delivery methods and a growing emphasis on personalized medicine. For market participants, these developments are anticipated to present lucrative revenue growth possibilities. The market revenue is expected to experience strong growth during the forecast period due to these R&D efforts.
Several therapeutics previously only available by prescription are progressively becoming over-the-counter (OTC) medications, one of the most pervasive market trends observed in drugs treating atopic keratoconjunctivitis. Switching from a prescription-only to an OTC drug has many benefits. One benefit of this process is the increased accessibility of more practical and affordable choices, encouraging more people to use these therapeutics. The U.S. FDA oversees this switching procedure, which is also thought to be highly regulated and scientifically rigorous, allowing an increasing number of patients with atopic keratoconjunctivitis allergies to have direct access to various therapeutics.
However, despite a crucial and growing need for atopic keratoconjunctivitis treatments, there is a poor level of public awareness of eye conditions and eye health. The numerous symptoms of eye allergies, which can be treated or rectified quickly with appropriate diagnostics and medications, are not understood well. Patients rarely see ophthalmologists unless there is a serious or serious symptomatic disease. Most of the time, atopic keratoconjunctivitis symptoms like chronic itching are disregarded and improperly diagnosed, significantly limiting the number of patients who can be treated with prescription medications. One of the key factors limiting the growth of the global market is adverse treatment reactions. Even though the majority of the time, patients do not experience any fatal or life-threatening symptoms, some negative side effects include eye burning, stinging, irritation, headaches, runny or stuffy noses, a sour flavor in the mouth, and greater sensitivity to light may happen. Therefore, these factors could prevent these therapeutics from being used widely, resulting in slower market development during the forecast period.
Atopic Keratoconjunctivitis Market Ecosystem
The global atopic keratoconjunctivitis market is analyzed from the following perspectives: drug class, distribution channel, and region.
Atopic Keratoconjunctivitis Market by Drug Class
[56868]
Based on the drug classes, the global atopic keratoconjunctivitis market is segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, antibiotics, antivirals, and others.
The nonsteroidal anti-inflammatory drugs (NSAIDs) segment accounts for the largest revenue share of the global Atopic Keratoconjunctivitis market in 2022. Nonsteroidal anti-inflammatory drugs (NSAIDs) are used more frequently in ophthalmology to treat cystoid macular edema after cataract surgery, control scleritis, and lessen inflammation and miosis. They may also alleviate the postoperative discomfort and photophobia related to refractive surgery and the itchiness brought on by atopic keratoconjunctivitis. The U.S. Food and Drug Administration has recently authorized new topical NSAIDs and reformulated previously approved NSAIDs. Different pharmacokinetics and dosing intervals result from these additions and modifications, which may have therapeutic benefits. Due to their concentrated localized impact and diminished systemic side effects, topical NSAIDs have grown in popularity. These improvements in formulation and approval give medical professionals more choices for treating patients' pain and inflammation. The patient may control the chronic allergies with nonsteroidal anti-inflammatory drugs, which are antihistamines and antihistamine/mast cell stabilizers, such as Patanol and Pataday, Bepreve, Lastacaft, and Elestat. Topical nonsteroidal anti-inflammatory drugs NSAIDs combined with cold compresses for one week can help the in faster relief. NSAIDs reduce itching but only partially inhibit the inflammatory cascade and do not prevent histamine. They prevent cyclooxygenase from converting arachidonic acid into lipid-based inflammatory agents like prostaglandins. Because of this mode of action, less prostaglandin is produced.
Atopic Keratoconjunctivitis Market by Distribution Channel
Based on the distribution channels, the global atopic keratoconjunctivitis market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment accounted for the largest revenue share of the global atopic keratoconjunctivitis market 2022. Hospital pharmacies are significant drivers of the growth of the global market and play a critical part in managing atopic keratoconjunctivitis. Patients can receive medications from hospital pharmacies that might not be offered in other environments. Hospital pharmacies can also provide specialty services like compounding, which entails creating unique medications catered to each patient's requirements. As a result, patients may receive the finest care available for their diseases.
Additionally, hospital pharmacies can collaborate closely with other medical specialists to offer coordinated and specialized treatment for patients with atopic keratoconjunctivitis. By making sure that medications are accurately dispensed and monitored, hospital pharmacies can also aid in lowering prescription errors and unfavorable drug reactions. This may lead to more satisfied patients and improved treatment results. As a result, medication adherence increases, reducing the risk of negative side effects. These pharmacies may educate patients about their medications and how to take them correctly. Atopic keratoconjunctivitis-related clinical trials and other study types can be conducted at these pharmacies. This can support the creation of novel treatments and medications for the condition, helping patients and fostering market trends.
Atopic Keratoconjunctivitis Market by Region
Based on the region, the global Atopic Keratoconjunctivitis market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the largest revenue share of the global Atopic Keratoconjunctivitis market in 2022. The substantial patient population suffering from ocular allergies is one of the most significant market drivers in terms of revenue share in developing the global atopic keratoconjunctivitis market. Over 15% of the world population is thought to be affected by allergies, a serious medical issue. Because an allergic tendency tends to affect many body organs, the patient may experience symptoms that pertain to various organ systems. However, the ocular component is thought to be the most noticeable and incapacitating aspect of an allergy because it causes persistent and incapacitating symptoms like eye itching and watering, which causes significant irritation. For instance, the American Academy of Allergy, Asthma & Immunology estimates 2020, 50 million Americans experienced allergic conjunctivitis. Major pharmaceutical companies emphasize the research and development (R&D) of efficient therapeutics due to the high prevalence of the diseases, as seen from the robust pipeline of products in the works. In March 2023, the pipeline drug candidate of Dupilumab by Andover Eye Associates entered the Phase II of clinical trials in the U.S. to treat atopic keratoconjunctivitis. Such developments will further propel market growth shortly.
Competitive Landscape of Atopic Keratoconjunctivitis Market
Notable market participants operating in the global atopic keratoconjunctivitis market:
Strategic Development in Atopic Keratoconjunctivitis Market
Atopic keratoconjunctivitis is a long-term allergic disease affecting the eyelids and front surface of the eye. Many patients with the skin disease atopic dermatitis are affected.
The increasing risk of acquiring several types of allergies high demand for novel therapeutics are the main driving factors for the global atopic keratoconjunctivitis market revenue growth.
Lack of awareness and drugs related side effects are restraining the atopic keratoconjunctivitis market revenue growth.
Key companies operating the global atopic keratoconjunctivitis market are Bausch Health Companies Inc., Merck & Co. Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Amorphex.
The global atopic keratoconjunctivitis market is expected to grow at a revenue CAGR of 7.2% during the forecast period from 2023 to 2031.
*Insights on financial performance are subject to the availability of information in the public domain